skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Immune Checkpoint Inhibition in Head and Neck Cancer

Frontiers in oncology, 2018-08, Vol.8, p.310-310 [Peer Reviewed Journal]

COPYRIGHT 2018 Frontiers Research Foundation ;Copyright © 2018 Forster and Devlin. 2018 Forster and Devlin ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2018.00310 ;PMID: 30211111

Full text available

Citations Cited by
  • Title:
    Immune Checkpoint Inhibition in Head and Neck Cancer
  • Author: Forster, Martin David ; Devlin, Michael-John
  • Subjects: cancer immunology ; cancer immunotherapy ; Care and treatment ; Cellular proteins ; Development and progression ; Enzymes ; Genetic aspects ; Head and neck cancer ; head and neck squamous cell carcinoma ; Health aspects ; immune checkpoint inhibitors ; Immunology ; Regulation ; Squamous cell carcinoma
  • Is Part Of: Frontiers in oncology, 2018-08, Vol.8, p.310-310
  • Description: Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC. Immune checkpoint inhibitors, which aim to hinder the inhibitory interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, have demonstrated durable improvements in patient outcomes in advanced / metastatic HNSCC, with both pembrolizumab and nivolumab being granted FDA approval in 2016. There are numerous ongoing clinical trials exploring the role of checkpoint inhibitors both as single agents and in combination, administered with established treatment modalities such as chemotherapy and radiotherapy, as well as alongside other novel immune modulators. These trials are not limited to advanced / metastatic HNSCC, but also to the neo-adjuvant or adjuvant settings. As studies complete and more results become available, the role immunotherapy agents will have within the treatment strategies for HNSCC may change, with increasing biomarker selection resulting in personalized therapy aiming to further improve patient outcomes.
  • Publisher: Switzerland: Frontiers Research Foundation
  • Language: English
  • Identifier: ISSN: 2234-943X
    EISSN: 2234-943X
    DOI: 10.3389/fonc.2018.00310
    PMID: 30211111
  • Source: TestCollectionTL3OpenAccess
    GFMER Free Medical Journals
    PubMed Central
    Alma/SFX Local Collection
    ROAD: Directory of Open Access Scholarly Resources
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait